GLP-1 Peptides and Glaucoma Risk: What We Know and What to Watch

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/glp-1-peptides-and-glaucoma-risk-what-we-know-and-what-to-watchTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction GLP-1 receptor agonists (glucagon-like peptide-1 analogs) are a class of medicines originally developed to treat type 2 diabetes. By mimicking a natural gut hormone (GLP-1), drugs like semaglutide (Ozempic®, Wegovy®) and liraglutide (Victoza®, Saxenda®) help lower blood sugar and often cause weight loss 7{reference-type="ref"}. They are now used by millions of patients worldwide for diabetes and obesity. Interestingly, recent studies have observed that people taking these GLP-1 medicines seem to develop glaucoma – an eye disease that damages the optic nerve – less often than expected. In this article, we explain what GLP-1 agonists are, summarize the human evidence about glaucoma risk, describe how they might protect the eye, and discuss what kind of proof (randomized trials) is still needed. We also cover safety and regulatory issues. What Are GLP-1 Receptor Agonists? GLP-1 (glucagon-like peptide-1) is a natural hormone that helps the body release insulin and control appetite after eating. GLP-1 receptor agonists are medicines designed to act like GLP-1. Besides semaglutide and liraglutide, other examples include exenatide (Byetta®) and dulaglutide (Trulicity®). These drugs improve glycemic control (lower blood sugar) and often promote significant weight loss () (). Some newer GLP-1 agonists even come in pill form (e.g. oral semaglutide) (). Because they have “pleiotropic” effects, they also protect blood vessels and reduce inflammation in various parts of the body (). For instance, research in animals and humans has found that GLP-1 agonists improve heart and kidney health in diabetes (). GLP-1 RAs and the Eye GLP-1 receptors are present in many eye tissues, including nerve cells and blood vessel cells in the retina (). Laboratory studies show that activating these receptors can have powerful effects in the eye. GLP-1 drugs have anti-inflammatory, antioxidant, and neuroprotective actions in the retina (). For example, one experimental GLP-1 agonist (called NLY01) reduced damaging inflammation and prevented retinal ganglion cell death in a mouse model of glaucoma (). Another line of research found that GLP-1 analogs stabilize small blood vessels and the blood–retina barrier (the tight layer that protects the eye) (). In short, GLP-1 RAs have been shown to block multiple harmful processes in the eye – inflammation, oxidative stress, and nerve-cell damage – that are linked to glaucoma and other eye diseases () (). These findings have raised the idea that GLP-1 drugs might protect vision independently of their blood-sugar effects. Observational Evidence: Lower Glaucoma Rates Among GLP-1 Users? Several recent observational studies (looking at real-world patient data) have noted that people taking GLP-1 RAs develop glaucoma less often than similar patients who do not take them. For example, a U.S. insurance claims study compared about 1,961 new users of GLP-1 RAs to over 4,300 matched diabetic patients on other medications. After balancing the groups for age, gender, and diabetes control, the GLP-1 group had only 10 new cases of glaucoma (0.51%) versus 58 cases (1.33%) in controls. Statistically, this corresponded to a 44% lower hazard of glaucoma in the GLP-1 users (adjusted hazard ratio 0.56, 95% confidence interval 0.36–0.89, p=0.01) (). In plain language, GLP-1 treated patients had rSupport the show